Affimed (NASDAQ:AFMD) Sees Large Decrease in Short Interest

Affimed (NASDAQ:AFMD) was the recipient of a significant decrease in short interest in March. As of March 15th, there was short interest totalling 602,500 shares, a decrease of 14.9% from the February 28th total of 708,100 shares. Based on an average daily volume of 186,000 shares, the short-interest ratio is currently 3.2 days. Approximately 4.6% of the shares of the company are sold short.

Affimed Stock Down 1.8 %

AFMD opened at $0.71 on Wednesday. Affimed has a one year low of $0.70 and a one year high of $8.95. The business’s fifty day moving average is $0.97 and its two-hundred day moving average is $2.04. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. StockNews.com began coverage on Affimed in a research report on Tuesday. They set a “sell” rating on the stock. Wells Fargo & Company cut their price objective on Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a research report on Thursday, December 12th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Affimed in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $13.50.

Institutional Investors Weigh In On Affimed

A number of large investors have recently added to or reduced their stakes in AFMD. Jane Street Group LLC acquired a new position in Affimed during the third quarter worth about $44,000. FMR LLC lifted its stake in Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 4,086 shares in the last quarter. Intellectus Partners LLC grew its holdings in Affimed by 34.0% during the 4th quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 32,053 shares during the last quarter. Northern Trust Corp purchased a new position in Affimed during the fourth quarter worth $218,000. Finally, Point72 Asset Management L.P. raised its holdings in shares of Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after acquiring an additional 15,108 shares during the last quarter. 30.82% of the stock is owned by institutional investors and hedge funds.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.